File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical efficacy and safety of buyang huanwu decoction for acute ischemic stroke: a systematic review and meta-analysis of 19 randomized controlled trials

TitleClinical efficacy and safety of buyang huanwu decoction for acute ischemic stroke: a systematic review and meta-analysis of 19 randomized controlled trials
Authors
KeywordsBrain ischemia
Central nervous system agents
Clinical effectiveness
Drug safety
Chinese drug
Issue Date2012
PublisherHindawi Publishing Corporation. The Journal's web site is located at http://www.hindawi.com/journals/ecam/
Citation
Evidence - based Complementary and Alternative Medicine, 2012, v. 2012, article no. 630124 How to Cite?
AbstractBuyang Huanwu Decoction (BHD) is a well-known traditional Chinese herbal prescription for treating stroke-induced disability. The objective of this study was to evaluate the efficacy and safety of BHD for acute ischemic stroke. A systematic literature search was performed in 6 databases until February 2012. Randomized controlled clinical trials (RCTs) that evaluate efficacy and safety of BHD for acute ischemic stroke were included. Nineteen RCTs with 1580 individuals were identified. The studies were generally of low methodological quality. Only one of the trial included death or dependency as a primary outcome measure. Only 4 trials reported adverse events. Meta-analysis showed the clinical effective rate of neurological deficit improvement favoring BHD when compared with western conventional medicines (WCM), P < 0.001. There is significant difference in the neurologic deficit score between the BHD treatment group and the WCM control group, P < 0.001. In Conclusion, BHD appears to improve neurological deficit and seems generally safe in patients with acute ischemic stroke. However, the current evidence is insufficient to support a routine use of BHD for acute ischemic stroke due to the poor methodological quality and lack of adequate safety data of the included studies. Further rigorously designed trials are required.
Persistent Identifierhttp://hdl.handle.net/10722/180326
ISSN
2015 Impact Factor: 1.931
2015 SCImago Journal Rankings: 0.615
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHao, CZen_US
dc.contributor.authorWu, Fen_US
dc.contributor.authorShen, Jen_US
dc.contributor.authorLu, Len_US
dc.contributor.authorFu, DLen_US
dc.contributor.authorLiao, WJen_US
dc.contributor.authorZheng, GQen_US
dc.date.accessioned2013-01-21T01:36:32Z-
dc.date.available2013-01-21T01:36:32Z-
dc.date.issued2012en_US
dc.identifier.citationEvidence - based Complementary and Alternative Medicine, 2012, v. 2012, article no. 630124en_US
dc.identifier.issn1741-427X-
dc.identifier.urihttp://hdl.handle.net/10722/180326-
dc.description.abstractBuyang Huanwu Decoction (BHD) is a well-known traditional Chinese herbal prescription for treating stroke-induced disability. The objective of this study was to evaluate the efficacy and safety of BHD for acute ischemic stroke. A systematic literature search was performed in 6 databases until February 2012. Randomized controlled clinical trials (RCTs) that evaluate efficacy and safety of BHD for acute ischemic stroke were included. Nineteen RCTs with 1580 individuals were identified. The studies were generally of low methodological quality. Only one of the trial included death or dependency as a primary outcome measure. Only 4 trials reported adverse events. Meta-analysis showed the clinical effective rate of neurological deficit improvement favoring BHD when compared with western conventional medicines (WCM), P < 0.001. There is significant difference in the neurologic deficit score between the BHD treatment group and the WCM control group, P < 0.001. In Conclusion, BHD appears to improve neurological deficit and seems generally safe in patients with acute ischemic stroke. However, the current evidence is insufficient to support a routine use of BHD for acute ischemic stroke due to the poor methodological quality and lack of adequate safety data of the included studies. Further rigorously designed trials are required.-
dc.languageengen_US
dc.publisherHindawi Publishing Corporation. The Journal's web site is located at http://www.hindawi.com/journals/ecam/-
dc.relation.ispartofEvidence - based Complementary and Alternative Medicineen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectBrain ischemia-
dc.subjectCentral nervous system agents-
dc.subjectClinical effectiveness-
dc.subjectDrug safety-
dc.subjectChinese drug-
dc.titleClinical efficacy and safety of buyang huanwu decoction for acute ischemic stroke: a systematic review and meta-analysis of 19 randomized controlled trialsen_US
dc.typeArticleen_US
dc.identifier.emailShen, J: shenjg@hku.hken_US
dc.identifier.emailZheng, GQ: gq_zheng@sina.com, gq zheng@sohu.com-
dc.identifier.authorityShen, J=rp00487en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1155/2012/630124-
dc.identifier.pmid23193426-
dc.identifier.pmcidPMC3491750-
dc.identifier.scopuseid_2-s2.0-84868697095-
dc.identifier.hkuros212910en_US
dc.identifier.volume2012, article no. 630124en_US
dc.identifier.isiWOS:000310613200001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats